T J Stinson
Overview
Explore the profile of T J Stinson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bennett C, Hynes D, Godwin J, Stinson T, Golub R, Appelbaum F
Cancer Invest
. 2001 Aug;
19(6):603-10.
PMID: 11486703
Considerable morbidity, mortality, and economic costs result during remission induction therapy for elderly patients with acute myeloid leukemia (AML). In this study, the economic costs of adjunct granulocyte colony stimulating...
2.
Knox K, Adams J, Djulbegovic B, Stinson T, Tomor C, Bennet C
Ann Oncol
. 2001 Feb;
11(12):1591-5.
PMID: 11205468
Purpose: Our prior study found that pharmaceutical-sponsored and non-profit sponsored analyses differed in their published assessments of the economic value of six new oncology drugs. In this study, we expand...
3.
Bennett C, Stinson T
Cancer Invest
. 2001 Feb;
18(3):261-8.
PMID: 10754993
For the practicing oncologist, balancing quality of care with cost containment has become an unavoidable challenge. The development of new technologies, increased patient awareness, growth of managed care, and aging...
4.
Stinson T, Adams J, Bishop M, Kruse S, Tarantolo S, Bennet C
Bone Marrow Transplant
. 2000 Oct;
26(6):663-6.
PMID: 11041569
Hematopoietic colony-stimulating factors (CSF) decrease the duration of neutropenia following stem cell transplantation (SCT). With CSF-mobilized allogeneic blood SCT (alloBSCT), the yields of CD34+ cells are several-fold higher than in...
5.
Bennett C, Stinson T, Vogel V, Robertson L, Leedy D, OBrien P, et al.
J Clin Oncol
. 2000 Aug;
18(15):2805-10.
PMID: 10920127
Purpose: Medical care for clinical trials is often not reimbursed by insurers, primarily because of concern that medical care as part of clinical trials is expensive and not part of...
6.
Bennett C, Stinson T, Laver J, Bishop M, Godwin J, Tallman M
Leuk Lymphoma
. 2000 Mar;
37(1-2):65-70.
PMID: 10721770
Colony stimulating factors reduce the duration of neutropenia following intensive chemotherapy in a variety of settings, but the advantages in the management of leukemia are inconclusive. The variations in clinical...
7.
Bennett C, Stinson T, Lane D, Amylon M, Land V, Laver J
Med Pediatr Oncol
. 2000 Feb;
34(2):92-6.
PMID: 10657867
Background: Growth factor use has been shown to ameliorate chemotherapy-induced neutropenia, leading to shorter hospital stays and lower use of parenteral antibiotics, two costly areas of cancer treatment. Prior reports...
8.
9.
Stinson T, Calhoun E, Yang T, Lurain J, Bennett C
Cancer Invest
. 1999 Dec;
17(8):559-65.
PMID: 10592762
Currently used options for salvage therapy for epithelial ovarian cancer include intravenously administered paclitaxel or topotecan and orally administered altretamine or etoposide. The response rates for these agents are similar...
10.
Friedberg M, Saffran B, Stinson T, Nelson W, Bennett C
JAMA
. 1999 Oct;
282(15):1453-7.
PMID: 10535436
Context: Recent studies have found that when investigators have financial relationships with pharmaceutical or product manufacturers, they are less likely to criticize the safety or efficacy of these agents. The...